144 related articles for article (PubMed ID: 35595716)
1. Functional Tumor Targeting Nano-Systems for Reprogramming Circulating Tumor Cells with In Situ Evaluation on Therapeutic Efficiency at the Single-Cell Level.
Ren XH; He XY; Xu C; Han D; Cheng SX
Adv Sci (Weinh); 2022 Jul; 9(21):e2105806. PubMed ID: 35595716
[TBL] [Abstract][Full Text] [Related]
2. Multi-Targeting Nano-Systems Targeting Heterogeneous Cancer Cells for Therapeutics and Biomarker Detection.
Ren XH; Han D; He XY; Guo T; Chen XS; Pang X; Cheng SX
Adv Healthc Mater; 2023 Feb; 12(4):e2202155. PubMed ID: 36333906
[TBL] [Abstract][Full Text] [Related]
3. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
4. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
5. Direct detection of intracellular miRNA in living circulating tumor cells by tumor targeting nanoprobe in peripheral blood.
Xu C; He XY; Ren XH; Cheng SX
Biosens Bioelectron; 2021 Oct; 190():113401. PubMed ID: 34119837
[TBL] [Abstract][Full Text] [Related]
6. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
8. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
9. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
11. A Multiple Targeting Nanoprobe for Identifying Cancer Metastatic Sites Based on Detection of Various mRNAs in Circulating Tumor Cells.
Han D; Ren XH; Liao XR; He XY; Guo T; Chen XS; Pang X; Cheng SX
Nano Lett; 2023 May; 23(9):3678-3686. PubMed ID: 37052638
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
13. A Multifunctional Delivery System for Remodulating Cell Behaviors of Circulating Malignant Cells to Prevent Cell Fusion.
Han D; He XY; Huang Y; Gao M; Guo T; Ren XH; Liao XR; Chen XS; Pang X; Cheng SX
Adv Sci (Weinh); 2023 Oct; 10(29):e2303309. PubMed ID: 37590231
[TBL] [Abstract][Full Text] [Related]
14. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
[TBL] [Abstract][Full Text] [Related]
15. Aptamer/Peptide-Functionalized Nanoprobe for Detecting Multiple miRNAs in Circulating Malignant Cells to Study Tumor Heterogeneity.
Han D; Ren XH; He XY; Chen XS; Pang X; Cheng SX
ACS Biomater Sci Eng; 2023 Oct; 9(10):5832-5842. PubMed ID: 37679307
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
17. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
18. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
19. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated genome editing of Shewanella oneidensis MR-1 using a broad host-range pBBR1-based plasmid.
Suzuki Y; Kouzuma A; Watanabe K
J Gen Appl Microbiol; 2020 Apr; 66(1):41-45. PubMed ID: 31447475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
